• Bio-Techne partnered with Refeyn to integrate its MauriceFlex icIEF fractionation system with Refeyn’s TwoMP mass photometry platform.
• Combined workflow targets bispecific antibody and biosimilar characterization, linking charge variants with size distribution and aggregation at single-molecule resolution.
• Companies expect a roughly four-hour process to cut development risk and speed biosimilar manufacturing by reducing reliance on multiple tests.
• Workflow was demonstrated on mosunetuzumab-axgb and a biosimilar, tracking size changes across charge-variant fractions under different conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Techne Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606040630PR_NEWS_USPR_____CG75452) on June 04, 2026, and is solely responsible for the information contained therein.